INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.58B / 21S · 3 late79 trades$24.55M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04CFCheng Chi Fung0B / 42S42 trades$15.33M
  5. 05RARothblatt Martine A0B / 33S33 trades$5.50M
  6. 06RJRubinstein Julie0B / 32S32 trades$5.55M
  7. 07LBLeach Bryan0B / 30S30 trades$7.97M
  8. 08AOAtay Oguzhan0B / 30S30 trades$7.55M
  9. 09JDJenkins William D Jr0B / 30S30 trades$13.38M
  10. 10BSBiswas Sanjit0B / 28S28 trades$22.33M

Form 4 transactions

65,929 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
322.0K sh
Nov 2, 2026
Page 61 of 1649
← PrevNext →
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
1,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
15.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,365 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
8,252 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
20.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
9,305 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,750 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
12.4K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
PM
Peabody MarkExecutive VP & Pres-Aerospace
ATROASTRONICS CORP
Option exercise
M$128K
4,820 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
100.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,989 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RL
Runnette Deirdre L.Chief Legal Officer
BMBLBumble Inc.
Tax withholding
F$238K
39.9K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MA
Merriman Dwight ADirector
MDBMongoDB, Inc.
Open-market sale · 10b5-1 plan
SELL$1.38M
3,963 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,375 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
1,875 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
100.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
19.5K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
169.1K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
27.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,293 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
9,129 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
JA
Jameson Jeremy AndrewEVP - Chief Credit Officer
MSBIMidland States Bancorp, Inc.
Tax withholding
F$56K
1,694 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
8,252 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
281.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$29K
1,075 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
4,977 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
958.1K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BH
Baker Eric HowardDirector, See Remarks, 10% Owner
STUBStubHub Holdings, Inc.
Tax withholding
F$110K
18.1K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
4,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
1,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
20.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
20.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  3. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  4. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  5. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  6. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  7. BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
  8. SELLBCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K